[精神分裂症认知障碍的药物治疗——希望与失望之间] - Suppr

[Pharmacotherapy of cognitive impairment in schizophrenia-Between hope and disappointment].

作者信息

Paulzen Michael, Toto Sermin

机构信息

Alexianer Zentrum für seelische Gesundheit Aachen/Gangelt, Alexianer Aachen GmbH, Alexianergraben 33, 52062, Aachen, Deutschland.

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Medizinische Fakultät, RWTH Aachen, Aachen, Deutschland.

出版信息

Nervenarzt. 2025 Jun 5. doi: 10.1007/s00115-025-01846-2.

DOI:10.1007/s00115-025-01846-2

PMID:40471234

Abstract

摘要

相似文献

[Pharmacotherapy of cognitive impairment in schizophrenia-Between hope and disappointment].

Nervenarzt. 2025 Jun 5. doi: 10.1007/s00115-025-01846-2.

The mediating role of spiritual well-being in the relationship between self-care agency and hope in patients diagnosed with schizophrenia: a cross-sectional and correlational study.

BMC Psychiatry. 2025 Jul 1;25(1):603. doi: 10.1186/s12888-025-07078-7.

Metformin-improved cognitive impairment in patients with schizophrenia is correlated with activation of tricarboxylic acid cycle and restored functional connectivity of hippocampus.

BMC Med. 2025 Jul 1;23(1):349. doi: 10.1186/s12916-025-04218-4.

The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis.

Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 8;121:110668. doi: 10.1016/j.pnpbp.2022.110668. Epub 2022 Oct 23.

Cognitive impairment in schizophrenia is associated with prefrontal-striatal functional hypoconnectivity and striatal dopaminergic abnormalities.

J Psychopharmacol. 2024 Jun;38(6):515-525. doi: 10.1177/02698811241257877. Epub 2024 Jun 10.

The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis.

Psychol Med. 2017 Apr;47(6):1030-1040. doi: 10.1017/S0033291716003366. Epub 2016 Dec 29.

Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review.

Schizophr Res. 2018 Feb;192:16-29. doi: 10.1016/j.schres.2017.04.015. Epub 2017 Apr 14.

Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Am J Geriatr Psychiatry. 2016 Oct;24(10):923-39. doi: 10.1016/j.jagp.2016.03.013. Epub 2016 Apr 29.

Neurostructural, Neurofunctional, and Clinical Features of Chronic, Untreated Schizophrenia: A Narrative Review.

Schizophr Bull. 2025 Mar 14;51(2):366-378. doi: 10.1093/schbul/sbae152.

Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.

Cochrane Database Syst Rev. 2015 Dec 1;2015(12):CD009221. doi: 10.1002/14651858.CD009221.pub2.

本文引用的文献

[Antipsychotic drugs beyond the dopamine D blockade-Xanomeline-trospium as beacon of hope?].

Nervenarzt. 2025 May;96(3):304-308. doi: 10.1007/s00115-025-01830-w. Epub 2025 Apr 22.

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27.

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366(20)30513-7.

Glutamate hypothesis in schizophrenia.

Psychiatry Clin Neurosci. 2019 May;73(5):204-215. doi: 10.1111/pcn.12823. Epub 2019 Mar 6.

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

Biol Psychiatry. 2017 Jul 1;82(1):8-16. doi: 10.1016/j.biopsych.2016.11.014. Epub 2016 Dec 15.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.

Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.

Front Pharmacol. 2012 Nov 26;3:195. doi: 10.3389/fphar.2012.00195. eCollection 2012.

Glutamate signaling in the pathophysiology and therapy of schizophrenia.

Pharmacol Biochem Behav. 2012 Feb;100(4):665-77. doi: 10.1016/j.pbb.2011.03.023. Epub 2011 Apr 1.

Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

World Psychiatry. 2008 Feb;7(1):22-8. doi: 10.1002/j.2051-5545.2008.tb00142.x.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. doi: 10.1016/j.biopsych.2004.06.023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Pharmacotherapy of cognitive impairment in schizophrenia-Between hope and disappointment].

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献